Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
Rotuxemab and Asparigenase Adherence
The hypersensitivity rate is much, much, much higher than Pegasparigenase. BFM back bones probably have higher inactivation and hypersensitivity to Native Akolai. Adding something to reduce the hypersensitivity could dramatically improve EFS. It's unclear whether the benefit is due to Rotuxemab actually having an anti-lucemic effect or is it due to preventing asparigenase reactions prevented the less use of asparigen enzyme in the control arm? It's unclear.
Transcript
Play full episode
